التفاصيل البيبلوغرافية
| العنوان: |
Phase I clinical trial of temsirolimus and perifosine for recurrent glioblastoma. |
| المؤلفون: |
Kaley, Thomas J., Panageas, Katherine S., Pentsova, Elena I., Mellinghoff, Ingo K., Nolan, Craig, Gavrilovic, Igor, DeAngelis, Lisa M., Abrey, Lauren E., Holland, Eric C., Omuro, Antonio, Lacouture, Mario E., Ludwig, Emmy, Lassman, Andrew B. |
| المصدر: |
Annals of Clinical & Translational Neurology; Apr2020, Vol. 7 Issue 4, p429-436, 8p |
| مصطلحات موضوعية: |
OLIGODENDROGLIOMAS, GLIOMAS, BRAIN tumors, KARNOFSKY Performance Status, CEREBRAL hemorrhage, CLINICAL trials |
| مستخلص: |
Purpose: Malignant glioma (MG) is the most deadly primary brain cancer. Signaling though the PI3K/AKT/mTOR axis is activated in most MGs and therefore a potential therapeutic target. The mTOR inhibitor temsirolimus and the AKT inhibitor perifosine are each well‐tolerated as single agents but with limited activity reclinical data demonstrate synergistic anti‐tumor effects from combined treatment. Therefore, we initiated a phase I trial of combined therapy in recurrent MGs to determine safety and a recommended phase II dose. Methods: Adults with recurrent MG, Karnofsky Performance Status ≥ 60 were enrolled, with no limit on the number of prior therapies. Temsirolimus dose was escalated using standard 3 + 3 design from 15 mg to 170 mg administered once weekly. Perifosine was fixed as a 600 mg load on day 1 followed by 100 mg nightly (single agent MTD) until dose level 7 when the load increased to 900 mg. Results: We treated 35 patients with with glioblastoma (17) or other MGs (18; including nine anaplastic astrocytoma, nine anaplastic oligodendroglioma, one anaplastic oligoastrocytoma, and two low grade astrocytomas with radiographic transformation to MG). We observed five dose‐limiting toxicities (DLTs): one at dose level 3 (50mg temsirolimus), then two at dose level 7 expansion (170 mg temsirolimus), and then two more at dose level 6 expansion (170 mg temsirolimus). DLTs included thrombocytopenia (n = 3), intracerebral hemorrhage (n = 1) and lung infection (n = 1). Conclusion: Combining the mTOR inhibitor temsirolimus dosed at 115 mg weekly and the AKT inhibitor perifosine dosed at 100 mg daily (following 600 mg load) is tolerable in heavily pretreated adults with recurrent MGs. [ABSTRACT FROM AUTHOR] |
|
Copyright of Annals of Clinical & Translational Neurology is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Complementary Index |
Full Text Finder